rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Pancreatic cancer diabetes differs from type 2 diabetes in GLP-1 and GIP responses, guiding diagnostic distinction

RPEP-138162025Toledo, Frederico G S; Li, Yisheng; Wang, Fuchenchu; Bellin, Melena D; Brand, Randall; Cusi, Kenneth; Fisher, William; Kudva, Yogish C; Park, Walter G; Saeed, Zeb I; Yadav, Dhiraj; Considine, Robert V; Graham, Sarah C; Andersen, Dana K; Serrano, Jose; Goodarzi, Mark O; Hart, Phil A
evidence
The takeaway

Pancreatic cancer-related diabetes shows distinct glucose homeostasis patterns from T2DM: different GLP-1 and GIP responses, altered insulin/glucagon dynamics, providing potential markers to distinguish PDAC-DM from T2DM for earlier cancer detection.

Different diabetes = different incretins

Pancreatic cancer diabetes has distinct GLP-1/GIP responses from T2DM—potential biomarkers for early cancer detection in new-onset diabetics

What the researchers found

PDAC-DM vs T2DM: different GLP-1 and GIP responses; altered insulin/glucagon dynamics; distinct glucose homeostasis patterns; potential for earlier cancer detection if distinguished from T2DM.

Why it matters

Misdiagnosing pancreatic cancer-related diabetes as T2DM delays cancer detection. Finding distinct incretin response patterns could enable screening tools that identify PDAC-DM early.

How the study worked

Comparative study of glucose homeostasis parameters in PDAC-DM versus T2DM patients.

What this study cannot tell us

Specific incretin differences not detailed in abstract preview. Sample sizes unclear. Distinguishing patterns may overlap significantly. Practical screening tool not yet developed.

How to read the evidence

Comparative clinical study. Important diagnostic insight.

When this study was published

Published in 2025.

The bigger picture

Pancreatic cancer has the worst prognosis of common cancers partly because it is diagnosed late. Using incretin response patterns to detect PDAC-DM could be a screening tool for early cancer detection in new-onset diabetes.

Questions still open

  • Could a GLP-1/GIP response test screen for pancreatic cancer in new-onset diabetes?
  • How sensitive and specific are the incretin pattern differences?
  • Should all new-onset diabetes patients be screened for PDAC?

Common questions

Can new diabetes be a sign of pancreatic cancer?
Yes—pancreatic cancer can cause diabetes as a first symptom. This study found that cancer-related diabetes has different patterns of gut hormone (GLP-1, GIP) responses than regular type 2 diabetes. If doctors can distinguish between them, pancreatic cancer could be caught much earlier.
How is pancreatic cancer diabetes different from type 2?
This study found multiple differences in how the body handles glucose, insulin, glucagon, and incretin hormones (GLP-1, GIP). These metabolic "fingerprints" could potentially be used as screening tests to identify which new diabetics might actually have pancreatic cancer.

Read the original research

Pancreatic cancer-related diabetes and type 2 diabetes differ in multiple aspects of glucose homeostasis.

Diabetologia, 68(12), 2854-2866

View on PubMed ↗Publisher’s paper ↗

Citation

Toledo, Frederico G S; Li, Yisheng; Wang, Fuchenchu; Bellin, Melena D; Brand, Randall; Cusi, Kenneth; Fisher, William; Kudva, Yogish C; Park, Walter G; Saeed, Zeb I; Yadav, Dhiraj; Considine, Robert V; Graham, Sarah C; Andersen, Dana K; Serrano, Jose; Goodarzi, Mark O; Hart, Phil A. (2025). Pancreatic cancer-related diabetes and type 2 diabetes differ in multiple aspects of glucose homeostasis.. Diabetologia, 68(12), 2854-2866. https://doi.org/10.1007/s00125-025-06543-y